Skip to main content
Equibles
XNCR logo

XNCR · Xencor Inc

Track XNCR — free

Use XNCR with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about XNCR

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$23.34 +0.35 (+1.52%) At close · Aug 14
Market Cap
$1.74B
Shares
74.35M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$23.34 Open$22.91 Day$22.50–23.45 52W close$7.44–23.34 Avg vol 30d1.1M Short int11.3M · 15.3% float · 8.8d Short vol66% Last earningsMay 6, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Dec 30, 2026 Est · unconfirmed · in 19 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 5, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +65%
above
Price vs 50-day avg +40%
above
RSI (14) 74
overbought
MACD trend Positive
52-week position 100%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +34%
trailing
6-month return +102%
trailing
YTD return +52%
this year
Relative strength +88%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $17 › 200d $14 — 50d above 200d
Institutional flow Accumulating
+1% holders QoQ · +33 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
15.26% of float · ▲ +4.6% MoM · 8.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
205 holders — near 3-yr high, broad support
Squeeze score 88
high risk · 0–100
Fundamentals
Fair
Revenue growth +14%
Y/Y
EPS growth +65%
Y/Y
Free cash flow $-138.3M
Balance sheet $65.7M
net debt
Quant / Vol
risk profile
Very High
Volatility 66%
annualized · 1-yr
Max drawdown −43%
past year
ATR 5.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed May 6, 2026
Cash, cash equivalents and marketable debt securities · end of 2026 $380M – $400M
Prior guidance period ended · from the 8-K filed Nov 5, 2025
Cash, cash equivalents and marketable debt securities · end of 2025 $570M – $590M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+65% Bullish
Price vs 50-day avg
+40% Bullish
RSI (14)
74 Bearish
MACD trend
Positive Bullish
52-week position
100% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $17 › 200d $14 — 50d above 200d
Institutional flow Accumulating
+1% holders QoQ · +33 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
15.26% of float · ▲ +4.6% MoM · 8.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
205 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $7 Now $23 · 100% Range high $23
vs 200-day avg +65% vs 50-day avg +40%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
XNCR
Xencor Inc
this stock
$1.74B +52.4% +13.7% — 15.3%
ONC
BeOne Medicines Ltd.
 $513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
 $52.94B +1.2% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
205
% held
111.7%
Net QoQ
-1.4M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
252
View
Short & Settlement
Short Interest Rising
Shares short
11.3M
Days to cover
8.8d
Change
+502.3K sh
View
Short Volume
Short vol %
66%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
67.3K
Value
$1.1M
As of
Jul 13, 2026
View
Off-Exchange
Off-exchange %
34.7%
Week of
Jul 6, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$125.6M
Net income (FY)
$-91.9M
EPS diluted
$-1.24
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 5, 2026
This year
14
View
Proposed Sales
Value
$89.4K
Shares
6.8K
Filed
Jun 18, 2026
View
Exempt Offerings
Offering
$25.0M
Filed
Nov 19, 2021
View
Earnings & Events
Earnings Calls
Last call
May 6, 2026
View

Performance

5D 20D 120D MTD YTD
XNCR +12.2% +33.6% +101.7% +15.5% +52.5%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY +11.8% +29.2% +88.0% +11.6% +38.6%
Key facts CIK 1326732 CUSIP 98401F105 13F (30d) 197 filings 192 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)